Refractory IHCA and OHCA Treated With ECMO

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Extracorporeal membrane oxygenation (ECMO) support has been suggested to improve the survival rate in patients with refractory cardiac arrest (CA). Recent studies have also highlighted the potential early application of this method in improving the prognosis of prolonged cardiac arrest both for in hospital CA (INHCA) and out of hospital CA (OHCA). The rationale for use of ECMO in these patients is to optimize early perfusion of vital organs, curing the cause of CA and waiting for the recovery of the injured myocardium. The investigators have created a flow-chart to decide which patients are eligible. The aims of this study are to evaluate if, with this flow-chart, the investigators are able to detect which patients have more probability of survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Simultaneous Renal Replacement Therapy on Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock Patients

NCT02870946

Cardiogenic Shock

UNKNOWN NA

Pre-hospital ECMO or Conventional Resuscitation for Refractory Cardiac Arrest

NCT06177730

Out of Hospital Cardiac Arrest

NOT_YET_RECRUITING NA

ECMO LEft Ventricle UNloading Strategy

NCT06766006

Shock, Cardiogenic Cardiac Arrest Extracorporeal Membrane Oxygenation Complication

RECRUITING

Outcome of Patients Treated With ECLS

NCT04405817

Cardiogenic Shock Cardiac Arrest Heart Failure +2 more

RECRUITING

Levosimendan for Veno-arterial ECMO Weaning

NCT04323709

Cardiogenic Shock Refractory Shock

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrest

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extracorporeal Membrane Oxygenation

All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.

ECMO

Intervention Type PROCEDURE

Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ECMO

Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults 18-75 years old
* In and out of hospital Witnessed Cardiac Arrest
* No-flow time \< 5 min. or VF,VT,TP as rhythm of presentation
* Low-flow time \< 45 min.
* End Tidal CO2 \> 10 after 20 min.of CPR

Exclusion Criteria

* Comorbidities such:
* Terminal Malignancy
* Aortic Dissection
* Severe Cardiac Failure without transplant indication
* Severe Aortic Valve Failure
* Known Severe Peripheral arteriopathy

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No